the University of Maryland Marlene and Stewart Greenebaum Cancer Center Trials

the University of Maryland Marlene and Stewart Greenebaum Cancer Center	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Baer, Maria

PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

	Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Initiation of new trial in Ph+ ALL
	Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL

Active, not recruiting

245

Europe, Canada, Japan, US, RoW

Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone

Takeda

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

08/22

07/27

NCT02878785: Decitabine and Talazoparib in Untreated AML and R/R AML

Completed

1/2

Decitabine, dacogen, talazoparib, BMN673; MDV3800

University of Maryland, Baltimore, Pfizer, Van Andel Research Institute

Acute Myeloid Leukemia

01/20

11/20

HQP1351CU101, NCT04260022: Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Recruiting

Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab, Blincyto

Ascentage Pharma Group Inc.

Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia

01/24

NCT04207190: Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Completed

Gemtuzumab Ozogamicin, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Talazoparib, BMN 673, BMN-673, Talazoparib Tosylate, Talzenna

Roswell Park Cancer Institute, Pfizer

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

05/24

06/24



	Diseases Companies Products Productz Mechanisms of Action Sites